Published: February 11, 2016

Introduction {#sec1}
============

Maturity-onset diabetes of the young (MODY) is a type of autosomal dominant monogenic diabetes classically characterized by non-ketotic, non-insulin-dependent diabetes occurring before the age of 25 years ([@bib25]). Many MODY genes are pancreatic developmental transcription factors, with the notable exception of *GCK*, *CEL*, and *INS*. Although MODY was discovered more than two decades ago, the molecular mechanisms underlying transcription factor MODY in humans is still largely unclear because mouse models do not fully recapitulate this disease ([@bib15]) and the lack of a suitable human model.

Patients with MODY5 commonly exhibit pancreatic hypoplasia due to an autosomal dominant mutation in the *HNF1B* gene ([@bib7]). *HNF1B* is a member of the complex pancreatic transcription factor network which includes *HNF1A* and *HNF4A*. HNF1B^+^ cells in the pancreatic trunk epithelium are multipotent pancreatic progenitors which play a role in endocrine and exocrine development ([@bib12]). Although MODY5 was discovered in 1997, to date the effects of an autosomal dominant mutation in *HN1B* on human pancreas development and the molecular mechanisms underlying pancreatic hypoplasia remain not fully understood. MODY5 phenotype in humans cannot be phenocopied by *Hnf1β*^+/−^ mice since they do not develop diabetes ([@bib12]), highlighting the need for a suitable human model to study the perturbations in pancreas development ([@bib25]).

Human-induced pluripotent stem cell (hiPSC)-derived pancreatic cells now provide an excellent opportunity to study this monogenic diabetes phenotype. In this study, we established a well-controlled MODY5-hiPSC pancreatic differentiation model to elucidate the molecular mechanisms underlying MODY5 pancreatic hypoplasia. We differentiated four control and six mutant hiPSC lines, and observed that mutant *HNF1B*^*S148L/+*^ elicits a compensatory increase in definitive endoderm (DE) and pancreatic transcription factor gene expression. Mutant *HNF1B*^*S148L*^ directly accounted for an increased *PDX1* gene expression. These pancreatic transcription factor network perturbations could possibly explain the occurrence of maturity-onset diabetes rather than neonatal diabetes despite pancreatic hypoplasia. Importantly, pancreatic *PAX6* gene expression, known to be important for pancreatic β-cell function, was distinctly down-regulated in MODY5 pancreatic progenitors, which in part explains the early-onset diabetes and pancreatic hypoplasia in MODY5 patients.

Results {#sec2}
=======

Establishment of a Human Stem Cell Model for MODY5 {#sec2.1}
--------------------------------------------------

We recently reported the derivation of several hiPSC lines from a MODY5 family ([@bib10]) for in vitro disease modeling of monogenic diabetes ([@bib26]). Our experimental design included a "node" comprising a healthy family member (N805-6) and two members of the family with an autosomal dominant (S148L) mutation in the *HNF1B* gene, of which one of them has developed diabetes (N805-2) whereas the other has not (N805-1) ([Figure 1](#fig1){ref-type="fig"}A). Three independent hiPSC lines from each subject were established (iN805-6A/B/C, iN805-1A/B/C, and iN805-2A/B/C) and verified for the absence or presence of the S148L (C443T in exon 2) mutation in the *HNF1B* gene ([Figures 1](#fig1){ref-type="fig"}B and [S1](#mmc1){ref-type="supplementary-material"}A).

We then set out to establish a human pancreatic differentiation protocol for disease modeling of MODY5 in vitro ([Figure 1](#fig1){ref-type="fig"}C) based on a chemically defined medium (no serum) ([@bib27]), which is a modified version of our recently reported protocol ([@bib24], [@bib28]). Careful time-course analyses of differentiated control hiPSCs (derived from AG16102) ([@bib26]) indicated that pluripotency factors *OCT4* and *NANOG* plummet by day 3, and that hiPSCs transit through *EOMES*+ *MIXL1*+ mesendoderm before differentiating into DE marked by *CXCR4*, *SOX17*, *GATA4*, and *GATA6* ([Figure 1](#fig1){ref-type="fig"}D).

Further differentiation toward foregut endoderm and pancreatic progenitors by day 17 revealed an up-regulation of numerous key pancreatic progenitor markers such as *ISL1*, *HLXB9*, *HNF1B*, *PAX6*, *SOX9*, *PDX1*, *PTF1A*, *RFX6*, *NEUROD1*, *HNF6*, *DLK1*, *SOX4*, and *MAFB*, indicating that our pancreatic differentiation protocol is suitable for studying the impact of *HNF1B* ^*S148L/+*^ mutation on early pancreatic development and its transcriptional network ([Figures 1](#fig1){ref-type="fig"}E and [S1](#mmc1){ref-type="supplementary-material"}B). Immunostaining on day 12 and fluorescence-activated cell sorting (FACS) analyses on day 17 further confirmed the protein expression of key pancreatic developmental genes ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1D). Since *HNF1B* transcripts exhibit peak expression between days 7 and 10, we performed genome-wide microarray analyses on day-10 differentiated control hiPSCs, and confirmed the up-regulation of pancreas-related genes such as *PDX1*, *HNF1B*, *ISL1*, *RFX6*, *PAX6*, *GATA4*, *GATA6*, *SOX9*, and *PTF1A*, and a reciprocal down-regulation of numerous pluripotency-related genes ([Figures 1](#fig1){ref-type="fig"}F and [Table S1](#mmc2){ref-type="supplementary-material"}). Gene ontology (GO) analyses on up- and down-regulated genes (fold change \>2) indicated general changes in developmental processes and possibly a down-regulation of vascular development ([Figure S2](#mmc1){ref-type="supplementary-material"}A).

MODY5-hiPSC-Derived Pancreatic Progenitors Exhibit a Compensatory Increase in DE and Pancreatic Markers but Down-Regulation of PAX6 Gene Expression {#sec2.2}
---------------------------------------------------------------------------------------------------------------------------------------------------

We first differentiated the MODY5-hiPSCs into DE (day 3), gut endoderm (days 5--7), and early foregut progenitors (day 10) ([Figure 2](#fig2){ref-type="fig"}). *Hnf1β* gene is expressed as early as embryonic day 8.75 (E8.75) in the mouse primitive gut/foregut ([@bib17]), corresponding to ∼days 3--7 of the hiPSC in vitro differentiation. Interestingly, we observed an early compensatory increase in DE markers *CXCR4*, *SOX17*, *FOXA2*, *GATA4*, and *GATA6* on day 5 and beyond ([Figure 2](#fig2){ref-type="fig"}) in the mutant hiPSCs, just when *HNF1B* gene is beginning to be expressed ([Figure 1](#fig1){ref-type="fig"}E; days 3--5). This suggests that the early (low) expression of mutant *HNF1B* ^*S148L/+*^ during gut endoderm development is already causing an early compensatory increase in DE and gut endoderm markers.

Given the phenotypic similarities in pancreatic agenesis/hypoplasia caused by *HNF1B*, *PDX1*, *PTF1A*, *GATA4*, and *GATA6* mutations, we hypothesized that the dorsal pancreatic agenesis in MODY5 (*HNF1B* ^*S148L/+*^) ([@bib10]) could be directly linked to the down-regulation of downstream pancreatic genes *GATA4*, *GATA6*, *PDX1*, and *PTF1A*. Surprisingly, time-course transcriptional analyses of MODY5-hiPSC-derived pancreatic progenitors indicate higher gene expression of *HNF1B*, *PDX1*, *GATA4*, and *GATA6* in mutant hiPSCs (iN805-1A/B/C and iN805-2A/B/C; three independent lines; each in biological triplicate) compared with two control hiPSCs (non-family-related control iAG16102 and family control iN805-6A/B; two independent lines; each in biological triplicate) ([Figure 3](#fig3){ref-type="fig"}A). These findings were also substantiated by immunostaining of HNF1B and PDX1 on day 12 ([Figure 3](#fig3){ref-type="fig"}B; representative of two to three hiPSC lines) and FACS analyses of SOX9 and PDX1 on day 17 ([Figure 3](#fig3){ref-type="fig"}C; two to three hiPSC lines per subject were pooled together) in MODY5-hiPSC-derived pancreatic progenitors.

Subsequently, to address the hypothesis that mutant *HNF1B* ^*S148L/+*^ results in its decreased expression and thus leads to pancreatic hypoplasia and MODY, we analyzed the transcriptional profile to potentially identify a gene(s) which is down-regulated in the mutant hiPSC-derived pancreatic progenitors. Contrary to expectations, we found a compensatory increase in *FOXA2*, *ISL1*, *HLXB9*, and *RFX6* ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C), suggesting that this set of genes (including *HNF1B*, *PDX1*, *GATA4*, and *GATA6*) play an important role in alleviating the negative effects of mutant HNF1B^S148L/+^ so as to delay the overall impact of pancreatic hypoplasia and/or mutant HNF1B^S148L/+^ on diabetes onset. Surprisingly, *PAX6* was the singular gene among the many examined to exhibit down-regulation in mutant hiPSC-derived pancreatic progenitors ([Figure 3](#fig3){ref-type="fig"}A). Following this candidate gene approach, we performed microarray analyses for cells obtained from days 0, 12, and 17 ([Figure S3](#mmc1){ref-type="supplementary-material"}A and [Table S2](#mmc3){ref-type="supplementary-material"}). Reassuringly, our genome-wide analyses indicated that our candidate gene approach has captured all the key changes in pancreatic genes: increase in *PDX1*, *ISL1*, *HNF1B*, *TCF2*, *RFX6*, *FOXA2*, *GATA4*, *GATA6*, and *HLXB9* (*MNX1*) expression in the mutant hiPSC-derived pancreatic progenitors ([Figure S3](#mmc1){ref-type="supplementary-material"}A). In addition, *PAX6* was also the most relevant pancreatic gene (expressed in our differentiation) to be down-regulated in the mutant hiPSC-derived pancreatic progenitors ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Further GO analyses on the up- and down-regulated genes (fold change \>2) on days 12 and 17 mostly reflected changes in developmental processes ([Figures S3](#mmc1){ref-type="supplementary-material"}B and S3C). Uniquely, neural development appeared to be more down-regulated in MODY5 pancreatic progenitors on day 17 ([Figure S3](#mmc1){ref-type="supplementary-material"}C).

We then performed chromatin immunoprecipitation (ChIP) analyses and confirmed that HNF1B binds onto the genomic loci of *HLXB9* and *HNF1B* ([Figure S3](#mmc1){ref-type="supplementary-material"}D), suggesting that these two genes could be the earliest mediators of pancreatic transcription factor network control. To evaluate whether the HNF1B mutation affected pancreatic progenitor cell growth, we performed a cell counting assay and, interestingly, observed that there is a huge retardation of cell growth from day 12 onward, when the mutant HNF1B protein exhibits peak expression ([Figure S3](#mmc1){ref-type="supplementary-material"}E). This strongly suggests that the mutant HNF1B protein affects pancreatic cell growth, thereby accounting for the pancreatic hypoplasia phenotype in MODY5.

Wild-Type HNF1B Suppresses, While Mutant HNF1B Increases, PDX1 Gene Expression {#sec2.3}
------------------------------------------------------------------------------

The compensatory increase in both *HNF1B* and *PDX1* gene expression in the mutant hiPSC-derived pancreatic progenitors prompted us to further investigate this molecular relationship. FACS analyses performed on day-12 differentiated control hiPSCs confirmed that 36.2% are PDX1^+^ ([Figure 4](#fig4){ref-type="fig"}A) whereas 91.4% are HNF1B^+^ ([Figure 5](#fig5){ref-type="fig"}A), corroborating their transcriptional profile ([Figure 1](#fig1){ref-type="fig"}E). We first performed luciferase assays to study the transcriptional regulation of cardinal pancreatic gene *PDX1* ([@bib21]) by HNF1B. Overexpression of *HNF1B* from days 10--12 in differentiated control hiPSCs surprisingly suppressed *PDX1* transcriptional activity, in both the ∼7 kb full-length *PDX1* promoter construct and a construct containing areas I--III of *PDX1* promoter (∼2.4 kb) known to be the principal control region of *PDX1* gene expression ([@bib9]) ([Figure 4](#fig4){ref-type="fig"}B). This indicates a repressive pattern of HNF1B whereby *HNF1B* gene expression is decreasing when *PDX1* is beginning to be expressed from days 10--12 ([Figure 1](#fig1){ref-type="fig"}E).

HNF1B protein functions either as a homodimer or a heterodimer with the structurally related HNF1A ([@bib16], [@bib18]). We thus overexpressed both *HNF1B* and *HNF1A* from days 10--12 in differentiated control hiPSCs, only to discover that HNF1A does not have any transcriptional regulatory effect on *PDX1*, at least during this early pancreatic progenitor stage when *PDX1* is beginning to be expressed ([Figure 4](#fig4){ref-type="fig"}C). This is consistent with the observation that HNF1A is expressed very late during pancreatic differentiation ([Figure S1](#mmc1){ref-type="supplementary-material"}D). Thus, the suppressive effect of HNF1B on *PDX1* transcriptional activity is likely due to homodimers in action.

Very little is known about the target genes of HNF1B in a developing pancreas. *HNF4A* is one potential candidate ([@bib29]). HNF1 binding sites have been found to be present in pancreas-/islet-specific P2 ([@bib29]) and P1 promoters ([@bib22]) of the *Hnf4α* gene ([@bib8]). Thus, we cloned both P1 and P2 promoters of *HNF4A*, and performed similar luciferase assays. Dismally, *HNF1B* overexpression did not have any effect on P1 promoter and only a very marginal effect on P2 promoter activity in our stem cell model on day 12 ([Figure S4](#mmc1){ref-type="supplementary-material"}A), suggesting that the regulation of *HNF4A* by HNF1B (or HNF1A) is likely apparent only at later stages of pancreatic development.

To delineate whether the wild-type *HNF1B* or mutant *HNF1B*^*S148L*^ allele is responsible for the compensatory increase in pancreatic gene expression ([Figure 3](#fig3){ref-type="fig"}A), we next overexpressed wild-type *HNF1B* or mutant *HNF1B*^*S148L*^ from days 7--10 in differentiated control hiPSCs. Interestingly, overexpression of mutant *HNF1B*^*S148L*^ resulted in an increase in *PDX1* gene expression but was insufficient to up-regulate other pancreatic transcription factors such as *GATA4*, *GATA6*, or *SOX9* ([Figures 4](#fig4){ref-type="fig"}D and [S4](#mmc1){ref-type="supplementary-material"}B). On the contrary, overexpression of wild-type *HNF1B* from days 7--10 did not alter the expression level of *PDX1* or other genes we investigated, including *GATA4*, *GATA6*, and *SOX9* ([Figures 4](#fig4){ref-type="fig"}E and [S4](#mmc1){ref-type="supplementary-material"}C). ChIP analyses performed on HNF1B also did not reveal binding on *PDX1* genomic loci ([@bib3] and data not shown). Last but not least, qPCR and western blot analyses confirmed that the HNF1B and HNF1A genes/proteins were overexpressed successfully ([Figures S4](#mmc1){ref-type="supplementary-material"}D and S4E). Together, these data indicate that mutant *HNF1B*^*S148L*^ (and not *HNF1B* or *HNF1A*) gene expression is responsible for the compensatory increase in *PDX1* gene expression in mutant hiPSC-derived pancreatic progenitors. The molecular mediator(s) of increased *GATA4* and *GATA6* gene expression in mutant hiPSC-derived pancreatic progenitors is unclear and requires further investigation.

HNF1B Is Not Directly Involved in Gene Regulation of PAX6 {#sec2.4}
---------------------------------------------------------

*Pax6* is known to be expressed during early pancreatic development (E9--9.5) in cells committed exclusively to the endocrine cell fate ([@bib1], [@bib19]). Among the transcription factors we analyzed, only *PAX6* transcripts were clearly down-regulated ([Figure 3](#fig3){ref-type="fig"}A). Since *PAX6* exhibits a similar (but right-shifted) gene-expression profile to that of *HNF1B*, we sought to investigate whether HNF1B or HNF1B^S148L^ is involved in the regulation of *PAX6* gene expression. FACS analyses on day-12 differentiated control hiPSCs (*PAX6* peak transcript expression) ([Figure 1](#fig1){ref-type="fig"}E), indicated that 27.2% are PAX6^+^, of which 22.0% are also HNF1B^+^ ([Figure 5](#fig5){ref-type="fig"}A). This percentage of PAX6^+^ cells is consistent with the report that PAX6 protein is detected only in a small subset of cells in the pancreatic endoderm at E9--9.5 ([@bib19]). Luciferase assays performed on day-10 differentiated control hiPSCs indicated that *PAX6* promoter is active ([Figure 5](#fig5){ref-type="fig"}B). However, overexpression of *HNF1B* and/or *HNF1A* had no impact, whereas overexpression of mutant *HNF1B*^*S148L*^ only resulted in a marginal suppression of *PAX6* promoter activity ([Figure 5](#fig5){ref-type="fig"}C). Overexpression of wild-type *HNF1B* from days 7--10 in differentiated control hiPSCs ([Figure 4](#fig4){ref-type="fig"}E) did not alter *PAX6* gene-expression levels ([Figure 5](#fig5){ref-type="fig"}D). Overexpression of mutant *HNF1B*^*S148L*^ alone ([Figure 4](#fig4){ref-type="fig"}D) was not sufficient to suppress *PAX6* gene-expression levels ([Figure 5](#fig5){ref-type="fig"}E). Furthermore, HNF1B was not found to bind onto the *PAX6* promoter region ([@bib3] and data not shown). This indicates that the decrease in *PAX6* gene expression is an indirect effect of the mutant *HNF1B*^*S148L/+*^ and is possibly a result of the altered pancreatic transcription factor network.

The loss of *Pax6* expression early on during pancreatic development reduces pancreatic insulin content ([@bib1], [@bib19]) and affects postnatal pancreatic β-cell function, which results in early-onset diabetes ([@bib1]). In this study, we found that *PAX6* gene expression is decreased in mutant (*HNF1B*^*S148L/+*^) hiPSC-derived pancreatic progenitors. To translate our findings to the MODY5 patients, we tracked the clinical phenotype of the N805 patients over time. N805-2 (*HNF1B*^*S148L/+*^) exhibited high fasting glucose levels (16.3 mmol/l) and required insulin (58--68 units/24 hr), whereas N805-1 (*HNF1B*^*S148L/+*^), who was not diabetic, presented with elevated fasting glucose levels (normal range: 4.0--6.0 mmol/l) and elevated 2-hr glucose levels after a standard oral glucose challenge (75 g) (impaired glucose tolerance range: 7.8--11.1 mmol/l) after the age of 8 years ([Figure 5](#fig5){ref-type="fig"}F). N805-2 presented low fasting insulin (2.4 mIE/l) whereas N805-1 exhibited a transition from normal to subnormal levels of fasting insulin, at 5.4 mIE/l (normal range: 6.0--27.0 mIE/l) ([Figure 5](#fig5){ref-type="fig"}F). As diabetes develops, plasma glucagon levels usually rise due to impaired α-cell glucose-sensing function and lack of appropriate suppression ([@bib6]). This scenario fits with the substantially elevated plasma glucagon levels (72.2 pmol/l) in the diabetic individual N805-2 and the moderately elevated plasma glucagon levels in the pre-diabetic individual N805-1 (46.9 pmol/l; normal range: 14.3--43 pmol/l) ([Figure 5](#fig5){ref-type="fig"}F).

Discussion {#sec3}
==========

We have successfully established a human stem cell model to study the molecular mechanisms underlying MODY5. Our experimental design, which includes a non-family control hiPSC line and three independent hiPSC lines from each of the three subjects in a MODY5 family, is a well-controlled experimental "node" which minimizes potential genetic background influence and line-to-line variation in hiPSC differentiation. While we observe *HNF1B* gene expression in the family control data to resemble that in the MODY5-hiPSC-derived pancreatic progenitors on rare occasions ([Figure 2](#fig2){ref-type="fig"}), suggesting initial genetic background effects (difference between control lines becomes attenuated later), the use of non-family control samples provides confidence in the overall distinct phenotypes we observed in our in vitro stem cell model. In addition, more than 90% of day-12 differentiated cells are HNF1B^+^, making our pancreatic differentiation protocol well suited for studying MODY5.

HNF1B has been reported to be a transcriptional activator ([@bib18]), but any positive regulation of *PDX1* gene expression by HNF1A and/or HNF1B could be specific to pancreatic β cells ([@bib2]) and not pancreatic progenitors, implying that HNF1B and/or HNF1A switch their binding partners during pancreatic development to regulate specificity in gene regulation.

We observed that mutant *HNF1B*^*S148L*^ (and not *HNF1B* or *HNF1A*) gene expression is responsible for the compensatory increase in *PDX1* gene expression in mutant hiPSC-derived pancreatic progenitors. This could, in part, be acting to counter the increased transcriptional repression by wild-type *HNF1B* ([Figures 3](#fig3){ref-type="fig"}B and 3C), although increasing *HNF1B* gene expression for 3 days from days 7 to 10 appears to be insufficient to significantly suppress *PDX1* gene expression ([Figure 4](#fig4){ref-type="fig"}E). This gene regulation is likely to be indirect, since we did not find HNF1B protein to be bound onto the genomic loci of *PDX1* ([@bib3]). It is interesting to note that β-cell-specific knockout of *Hnf1β* similarly results in an increase in *Pdx1* gene expression ([@bib31]), indicating that perturbations in *HNF1B* gene expression, either early during pancreatic development or in mature β cells, both prompt compensatory *PDX1* gene expression.

The presence of a wild-type *HNF1B* allele and the combinatorial effects of wild-type-mutant HNF1B dimers in MODY5 (*HNF1B*^*S148L/+*^) patients partly explains the compensatory up-regulation of numerous pancreatic transcription factors. The lack of down-regulation of critical pancreatic genes *PDX1*, *PTF1A*, *GATA4*, and *GATA6* implies that the mechanism underlying dorsal pancreatic agenesis in MODY5 is independent of these genes, which are also known to result in pancreatic agenesis/hypoplasia when mutated ([@bib4], [@bib14], [@bib20], [@bib21]). This compensation in pancreatic transcriptional network due to an *HNF1B* autosomal dominant mutation may also account for the diabetes onset relatively later in life seen in MODY5 compared with the early onset observed in genetic forms of neonatal diabetes ([@bib25]) ([Figure 5](#fig5){ref-type="fig"}G). In this context, it is interesting that the MODY5 subjects with dorsal pancreatic agenesis also exhibit compensatory increase in physiological acinar function with hypersecretion from the remaining ventral portions of the pancreas ([@bib30]).

*Hnf1β*^*−/−*^ mice with pancreatic agenesis exhibit loss of numerous pancreatic genes, including *Pax6* expression ([@bib12]). *Pax6*-deficient pancreatic progenitors that are unable to mature and reach terminal differentiation later in life cannot be rescued by postnatal neogenesis ([@bib1]). Thus, the reduction in pancreatic endocrine cell number in *Pax6*^*−/−*^ embryos ([@bib19]) and altered acinar structure ([@bib11]) could partly account for the pancreatic hypoplasia phenotype in MODY5 patients. Given that PAX6 directly regulates genes that regulate β-cell function ([@bib1], [@bib32]), we speculate that the loss of *PAX6* gene expression early on in the MODY5 patients also partly accounts for the β and α islet cell dysfunction, and contributes to their diabetic phenotype ([Figure 5](#fig5){ref-type="fig"}G). This concept is concordant with the observations that patients with *PAX6* heterozygous mutations also develop glucose intolerance ([@bib32], [@bib33]). It is interesting to note that administration of exendin-4, a glucagon-like peptide 1 receptor (GLP-1R) agonist, to *Pax6*^*+/*−^ mice can rescue the metabolic abnormalities observed, either via increased insulin secretion or β-cell regeneration ([@bib5]), suggesting a potential for treatment for patients lacking pancreatic *PAX6* gene expression, and the MODY5 patients in this study.

Collectively, we have evaluated the impact of a MODY5-causing point mutation (S148L) in the *HNF1B* gene on human pancreas development using a unique human stem cell model. We report molecular phenotypes (up- and down-regulation of pancreatic genes) when *HNF1B* is increasingly expressed from days 7 to 10, and observed that these phenotypes extend beyond the expression window of HNF1B. These data provide insights into the long-term impact of the MODY5 mutation on the pancreatic transcriptional network and the subsequent development of human pancreatic progenitors into mature functional endocrine cells. This is in agreement with [@bib13], who indicated that MODY5 is certainly due to defective morphogenesis of the pancreas. Future efforts to further differentiate these hiPSCs into pancreatic β cells will reveal the impact of transcriptional perturbations on β-cell formation and function.

Experimental Procedures {#sec4}
=======================

Cell Culture {#sec4.1}
------------

Informed consent was obtained from MODY5 patients. This study was reviewed and approved by the Institutional Review Boards at Haukeland University Hospital and Joslin Diabetes Center, and in accordance with the principles set out in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report. hiPSCs used were tested mycoplasma negative and were cultured as described previously ([@bib26], [@bib27]). hiPSCs were differentiated into pancreatic progenitors as described previously ([@bib27]). In general, 2--3 independent hiPSC lines per subject were used, and biological triplicates were used for each hiPSC line.

Sequencing of MODY5-hiPSCs {#sec4.2}
--------------------------

The method for sequencing has been described previously ([@bib26]).

qRT-PCR, Immunostaining, FACS, Western Blot, and ChIP Analyses {#sec4.3}
--------------------------------------------------------------

Methods for qRT-PCR, immunostaining, FACS, western blot ([@bib27]), and ChIP analyses ([@bib3], [@bib23], [@bib28]) have been described previously. p \< 0.05 indicates statistical significance by Student\'s t test (two-sided; equal variance). In general, qRT-PCR and immunostaining data of MODY5-hiPSC-derived cells are representative of one non-family control hiPSC line (iAG16102), two family control hiPSC lines (iN805-6A/C), and three lines each for the two MODY5 patients (iN805-1A/B/C and iN805-2A/B/C). All error bars indicate SD of three biological replicates. Two to three hiPSC lines per subject were pooled together before being set up in triplicate for FACS analyses. Primers and antibodies used are provided in [Table S3](#mmc4){ref-type="supplementary-material"}.

Microarray {#sec4.4}
----------

Microarray was performed by the Molecular Genetics Core Facility at Children\'s Hospital, Boston. Two biological replicates for undifferentiated and day-10 differentiated control hiPSCs were analyzed. One sample from iAG16102, iN805-6, iN805-1, and iN805-2 each was used for day-0, -12 and -17 analyses.

Gene Ontology Overrepresentation Analysis {#sec4.5}
-----------------------------------------

The overrepresentation of GO biological process categories was assessed using DAVID.

Overexpression Studies {#sec4.6}
----------------------

*HNF1B* gene was amplified from cDNA obtained from differentiated hPSCs using PfuUltra II Fusion HS DNA Polymerase with a melting temperature (Tm) of 50°C and extension at 72°C for 2 min. *HNF1B* cDNA was then subcloned into pCDH-FlagV5 vector using EcoRI and XhoI RE sites to obtain pCDH-h*HNF1B*. *HNF1B* cDNA was also subcloned into PCR-Blunt II-TOPO vector, and h*HNF1B*C443TF and h*HNF1B*C443TR primers were used to amplify *HNF1B*^*S148L*^ using PfuUltra II Fusion HS DNA Polymerase with an extension at 72°C for 5 min. *HNF1B*^*S148L*^ cDNA was then subcloned into pCDH-FlagV5 vector using EcoRI and XhoI RE sites to obtain pCDH-h*HNF1B*^*S148L*^. pcDNA3.1-h*HNF1A* was a gift from Y.-I. Chi. Primers used are provided in [Table S3](#mmc4){ref-type="supplementary-material"}. Day-6 differentiated control hiPSCs were split and replated onto 12-well plates. These cells were transduced with lentiviruses (multiplicity of infection 10, 20, 30 or 50, 100, 200) containing pCDH-*GFP*, pCDH-*HNF1B*, or pCDH-*HNF1B*^*S148L*^ on day 7, washed with PBS on day 8, and harvested on day 10.

Luciferase Assays {#sec4.7}
-----------------

h*PDX1* promoter (∼7 kb) was cloned into pGL4.10 using NheI and XhoI RE sites. h*PDX1* promoter/enhancer (areas I--III) was cloned into pGL4.23 using XhoI and BglII RE sites. h*HNF4A* P1 and P2 promoters were cloned into pGL4.10 using KpnI and XhoI RE sites. h*PAX6* promoter (346 bp) containing HNF1B and HNF1A binding sites was a gift from Y.-H. Zhou. Primers used are provided in [Table S3](#mmc4){ref-type="supplementary-material"}. Day-9 differentiated control hiPSCs were split and replated onto 12-well plates. These cells were transfected with h*PDX1* promoter, h*HNF4A* P1 or P2 promoter in the absence and presence of pCDH-*HNF1B*, and/or pcDNA3.1-h*HNF1A* on day 10 and harvested on day 12. Day-6 differentiated control hiPSCs were split and replated onto 12-well plates. These cells were transfected with h*PAX6* promoter in the absence and presence of pCDH-*GFP*, pCDH-*HNF1B*, pCDH-*HNF1B*^*S148L*^, and/or pcDNA3.1-h*HNF1A* on day 7 and harvested on day 10. The method for luciferase assay has been described previously ([@bib23]).

Hormone Assays {#sec4.8}
--------------

Glucagon was assessed with a radioimmunoassay from Millipore. This assay reports a precision (coefficient of variation) for high levels (72.4 pmol/l) of 10.1%, for intermediate levels (52.2 pmol/l) of 12.6%, and for low levels (28.8 pmol/l) of 9.2%. Prior to analysis, we collected blood samples in plasma tubes containing 250 kIU Trasvlol (Aprotinin) per ml of whole blood. This resulted in a final concentration of approximately 500 kIU Trasvlol per ml of serum or plasma, and the aliquot was frozen at −70°C.

Author Contributions {#sec5}
====================
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Accession Numbers {#app1}
=================

Microarray data have been uploaded to GEO with accession number GEO: [GSE74885](ncbi-geo:GSE74885){#intref0010}.
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![Establishment of a Human Stem Cell Model for MODY5\
(A) N805 family node pedigree for MODY5 family. Square denotes male, circles denote females, solid symbol denotes diabetes, NN denotes no mutation, and NM denotes mutation. N805-6 is a family control, N805-1 has *HNF1B*^*S148L/+*^ phenotype but no diabetes, whereas N805-2 has *HNF1B*^*S148L/+*^ phenotype and is diabetic.\
(B) S148L (C443T in exon 2) mutation (or lack thereof) in *HNF1B* has been verified in iN805 hiPSCs at least three times.\
(C--E) Schematic representation of a human pancreatic differentiation protocol for disease modeling of MODY5 in vitro. (C) CHIR99021 (CHIR) is a GSK-3 inhibitor whereas LY294002 (LY) is a PI3K inhibitor. Expression of (D) pluripotency (*OCT4* and *NANOG*), mesendoderm (*EOMES* and *MIXL1*), definitive endoderm (*CXCR4*, *SOX17*, *GATA4*, and *GATA6*) and (E) foregut endoderm (*ISL1*, *HLXB9*, *HNF1B*, *PAX6*, *SOX9*, *PDX1*, *PTF1A*, and *RFX6*) markers in control hiPSCs differentiated for 17 days. All error bars indicate SD of three biological replicates in an independent experiment.\
(F) Gene-expression heatmap of representative pluripotency, mesendoderm, definitive endoderm, and pancreas-related genes in undifferentiated (first two columns) and day-10 differentiated (last two columns) control hiPSCs (up-regulation in red, down-regulation in blue). The colors in the heatmap depict gene expression in units of SD from the mean across all samples. Asterisks indicate genes for which mutations are known to result in pancreatic hypoplasia/agenesis.\
See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![Transcriptional Perturbations in MODY5-hiPSC-Derived Early Pancreatic Progenitors\
Gene expression of *CXCR4*, *SOX17*, *FOXA2*, *GATA4*, *GATA6*, and *HNF1B* in a non-family control and in iN805 family hiPSCs differentiated for 0, 5, 7 and 10 days. Data are representative of at least two independent hiPSC lines per subject. Replicate experiments are presented. The experiments were replicated at least twice. All error bars indicate SD of three biological replicates in an independent experiment. See also [Figures S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![Transcriptional Perturbations in MODY5-hiPSC-Derived Pancreatic Progenitors\
(A) Gene expression of *HNF1B*, *PAX6*, *PDX1*, *PTF1A*, *GATA4*, and *GATA6* in a non-family control and in iN805 family hiPSCs differentiated for 0, 12, 14, and 17 days. Data are representative of at least two independent hiPSC lines per subject. Replicate experiments are presented. The experiments were replicated at least twice. All error bars indicate SD of three biological replicates in an independent experiment.\
(B) Immunostaining for HNF1B and PDX1 on iN805 hiPSCs differentiated for 12 days. Data are representative of at least two independent hiPSC lines per subject. The experiment was replicated at least twice. Scale bar, 200 μm.\
(C) The percentage of PDX1^+^ and SOX9^+^ cells after differentiation of iN805 hiPSCs (two to three hiPSC lines per subject were pooled together) for 17 days.\
See also [Figures S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}.](gr3){#fig3}

![Mutant HNF1B Is Responsible for the Increase in *PDX1* Gene Expression\
(A) The percentage of PDX1^+^ cells after differentiation of hiPSCs for 12 days.\
(B and C) Luciferase assay showing the effect of (B) *HNF1B* and/or (C) *HNF1A* overexpression on *PDX1* transcriptional activity in hiPSCs differentiated for 12 days.\
(D and E) Expression of pancreas-related (*HNF1B*, mutant *HNF1B*^*S148L/+*^, *PDX1*, *GATA4*, and *GATA6*) markers in hiPSCs differentiated for 10 days and overexpressing increasing amounts of (D) mutant *HNF1B*^*S148L*^ or (E) *HNF1B* from days 7--10. The replicate experiment for mutant *HNF1B*^*S148L*^ is presented.\
The experiments were replicated at least twice. All error bars indicate SD of three biological replicates in an independent experiment. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}

![HNF1B Is Not Directly Involved in Gene Regulation of *PAX6*\
(A) The percentage of HNF1B^+^ and PAX6^+^ cells after differentiation of hiPSCs for 12 days.\
(B and C) Luciferase assay showing (B) basal *PAX6* promoter activity and (C) the effect of *HNF1B* and/or *HNF1A* overexpression on *PAX6* promoter activity in hiPSCs differentiated for 10 days.\
(D and E) Expression of *PAX6* in hiPSCs differentiated for 10 days and overexpressing increasing amounts of (D) *HNF1B* or (E) mutant *HNF1B*^*S148L*^ from days 7--10. The experiments in (B) to (E) were replicated at least twice. All error bars indicate SD of three biological replicates in an independent experiment. ^∗^*p* \< 0.05 by two-sided Student\'s t test on three independent experiments.\
(F) Clinical characteristics of MODY5 patients including HbA1c (%), blood glucose (glu), insulin (INS), C-peptide (C-pep), and plasma glucagon (P-GCG) concentrations.\
(G) Model depicting the impact of mutant *HNF1B*^*S148L/+*^ on early human pancreas development. Mutant *HNF1B*^*S148L/+*^ evokes an early increase in definitive endoderm genes followed by a subsequent increase in pancreas-related foregut endoderm genes. Thus, although MODY5 patients typically develop pancreatic hypoplasia there is a low occurrence of neonatal diabetes. The decrease in early *PAX6* gene expression in pancreatic progenitors may partly account for the subsequent β-cell dysfunction in MODY5 patients.](gr5){#fig5}
